Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).
22 Gennaio 2024 - 4:15PM
Notification from the European Patent Office (EPO) regarding the
decision to grant their patent for drug compositions aiming to
eliminate bacterial promoters of colorectal cancer through
intraluminal application (RNX-051).
Pharma Equity Group's subsidiary
(Reponex Pharmaceuticals A/S) has received notification from the
European Patent Office (EPO) regarding the decision to grant their
patent for drug compositions aiming to eliminate bacterial
promoters of colorectal cancer through intraluminal application
(RNX-051).
22 January 2024
Company Announcement No. 02
Pharma Equity Group's subsidiary (Reponex
Pharmaceuticals A/S) has received notification from the European
Patent Office (EPO) about the decision to grant their patent for
drug compositions for the elimination of bacterial promoters of
colorectal cancer through intraluminal application (RNX-051).
Today's announcement signifies a significant
milestone as the EPO has approved EP patent application No.
3740286, encompassing Reponex's innovative treatment method. This
method focuses on the removal of the bacterial layer, also known as
biofilm, which shields cancerous growths in the colon or rectum. By
removing this protective barrier, the treatment aims to render
cancer cells more susceptible to the body's natural immune
defenses."We are very pleased that the EPO has now approved the
patent application for our treatment method, allowing us to protect
our product in such a crucial commercial domain," says Thomas Kaas
Selsø, CEO of Pharma Equity Group A/S.
Colorectal cancer poses a significant global
challenge. According to the World Health Organization (WHO) and The
International Agency for Research on Cancer (IARC), the global
market for colorectal cancer was estimated at USD 9.4 billion in
2020. Therefore, the need for innovative treatment methods is more
urgent than ever.
The patent is valid until 2039. With the
attainment of full Supplementary Protection Certificate (SPC)
extension, the validity will extend until 2044.
For further information, please contact:Thomas
Kaas Selsø, CEOPhone: +45 4022 2114E-mail:
tks@pharmaequitygroup.com
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing extensive
support, resources, and expertise to drive the development and
success of these projects. As a strategic partner, Pharma Equity
Group works closely with Reponex Pharmaceuticals, prioritizing the
advancement of innovative medical solutions and breakthrough
therapies. Every effort is currently directed towards ensuring the
utmost success and impact of Reponex Pharmaceuticals' medical
projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
- 2024 01 22 - Announcement no 02 - UK
Grafico Azioni Pharma Equity Group A/s (LSE:0REU)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Pharma Equity Group A/s (LSE:0REU)
Storico
Da Gen 2024 a Gen 2025